diflucortolone and isoconazole

Dermatomycoses are contagious superficial fungal infections, which are highly prevalent in developed and developing countries. Caused by a range of Epidermophyton, Microsporum and Trichophyton species, dermatomycoses manifest on glabrous skin as 'ringworm', an annular scaly lesion with a variable inflammatory component. Itch is the chief subjective symptom, particularly in tinea cruris. Unless lesions are extensive or resistant to local therapy, dermatomycoses of glabrous skin are treated with topical antifungal agents, such as imidazoles and allylamines. Studies show, however, that the addition of a topical corticosteroid to imidazole therapy increases the bioavailability and prolongs the activity of the antimycotic, while rapidly reducing inflammatory symptoms. Travocort is a combination of 1% isoconazole nitrate (ISN), a broad-spectrum imidazole with established antimicrobial activity and antimycotic efficacy, and 0.1% diflucortolone valerate (DFV), a potent topical corticosteroid with low systemic absorption and therefore a low risk of systemic glucocorticoid side-effects. In randomised, double-blind controlled clinical trials, Travocort therapy showed a more rapid onset of action, faster relief of itch and other inflammatory symptoms, improved overall therapeutic benefits and better mycological cure rate during the first 2 weeks of treatment compared with ISN monotherapy. Travocort is well tolerated and, because of prolonged ISN retention in the skin, provides antifungal protection against reinfection for some weeks after therapy.

Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Antifungal Agents; Child; Child, Preschool; Dermatomycoses; Diflucortolone; Double-Blind Method; Drug Combinations; Humans; Inflammation; Miconazole; Randomized Controlled Trials as Topic; Tinea; Treatment Outcome

Topics: Adolescent; Adult; Aged; Child; Clinical Trials as Topic; Dermatomycoses; Diflucortolone; Double-Blind Method; Drug Combinations; Female; Fluocortolone; Humans; Hypersensitivity; Imidazoles; Inflammation; Male; Miconazole; Middle Aged

Topics: Adolescent; Adult; Aged; Child; Clinical Trials as Topic; Dermatomycoses; Diflucortolone; Double-Blind Method; Drug Combinations; Female; Fluocortolone; Humans; Imidazoles; Male; Miconazole; Middle Aged; Ointments

Tinea corporis is a common mycotic infection in children. Staphylococcus aureus superinfections may be observed in atopic children with tinea corporis suffering from severe pruritus and consequent scratching.. From 2006 to 2011, we observed 288 children with mycologically proven tinea corporis. In 39 of them (13.5%) tinea corporis was superinfected by S. aureus: all these children were affected by atopic dermatitis. We interpreted these bacterial superinfections as the clinical result of scratching due to pruritus.. In 2012, we decided to treat all children with a single lesion of tinea corporis with a combination of 1% isoconazole nitrate and 0.1% diflucortolone valerate cream (one application/day for 5-7 days), followed by a treatment with isoconazole or clotrimazole or ciclopirox cream (two applications/day for two weeks).. From 2012 to 2014, we observed 108 children with tinea corporis confirmed by mycological examinations. Clinical and mycological recovery was observed in 93 of them (86.1%). Only four of these children (3.7%) developed S. aureus superinfections.. Our study in atopic children with tinea corporis superinfected by S. aureus confirms that a topical therapy with the association isoconazole-diflucortolone is useful and safe.

Topics: Administration, Topical; Antifungal Agents; Child; Child, Preschool; Dermatitis, Atopic; Diflucortolone; Drug Administration Schedule; Female; Humans; Male; Miconazole; Ointments; Staphylococcus aureus; Superinfection; Tinea; Treatment Outcome

Topics: Aged; Antifungal Agents; Dermatitis, Allergic Contact; Diflucortolone; Drug Combinations; Drug Eruptions; Female; Humans; Miconazole; Tinea

Undetected tinea pedis in a patient with diabetes can lead to serious bacterial infections with potentially serious consequences, such as foot amputations. Here we report on a 60-year-old patient with diabetes presenting with pain, severe pruritus, and malodour in the foot's interdigital area, and subsequently, diagnosed with inflammatory tinea pedis with bacterial superinfection. The patient was successfully treated with Travocort cream containing isoconazole nitrate 1% and diflucortolone valerate 0.1%; marked improvement occurred within 5 days.

Topics: Administration, Topical; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antifungal Agents; Diabetes Complications; Diflucortolone; Humans; Male; Miconazole; Middle Aged; Skin Diseases, Bacterial; Superinfection; Tinea Pedis; Treatment Outcome

There have been few published reports on the human transmission of Trichophyton mentagrophytes, a zoophilic fungus frequently occurring in pets. Here we report on 2 girls, living with a pet dwarf rabbit, who presented with inflammatory skin lesions positive for T. mentagrophytes and subsequently diagnosed as zoophile tinea faciei and tinea corporis. The patients were successfully treated with systemic terbinafine and 2-week therapy with Travocort cream containing isoconazole nitrate 1% and diflucortolone valerate 0.1%.

Topics: Administration, Oral; Administration, Topical; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antifungal Agents; Child; Diflucortolone; Environmental Exposure; Female; Humans; Miconazole; Naphthalenes; Pets; Rabbits; Terbinafine; Tinea; Treatment Outcome; Trichophyton

Trichophyton mentagrophytes is the dermatophyte species most commonly reported in cases of guinea pig-associated dermatophytosis (or guinea pig fungus) a condition that more often affects children than adults. In this case, a 13-year-old girl with recent direct contact with guinea pigs presented with a previously undertreated inflammatory skin lesion on the left side of her upper body, which was positive both for Trichophyton mentagrophytes and Staphylococcus epidermidis. The condition was subsequently diagnosed as tinea corporis due to Trichophyton mentagrophytes with concomitant bacterial infection and effectively treated with 2 weeks of twice-daily application of Travocort cream containing isoconazole nitrate 1% and diflucortolone valerate 0.1%. Visible improvement in the lesion was apparent after only 1 week of treatment.

Topics: Administration, Topical; Adolescent; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antifungal Agents; Diflucortolone; Environmental Exposure; Female; Gram-Positive Bacterial Infections; Guinea Pigs; Humans; Miconazole; Skin Diseases, Bacterial; Staphylococcus epidermidis; Tinea; Treatment Outcome; Trichophyton

Trichophytia infection, paraphrased cuddly toy mycosis, occurs primarily in prepubertal children, occasionally in infants and adults. The presented case shows the highly contagious infection of four family members with Trichophyton mentagrophytes. Effective treatment requires detailed diagnostic: identifying the dermatophyte, finding the infection source, treating the infection carriers. Tinea must be treated systemically and topically because of infectivity and ignitability. Systemic terbinafine or fluconazole treatment and topical fixed combination isoconazole nitrate/diflucortolone valerate are recommended.

Topics: Administration, Oral; Administration, Topical; Adult; Animals; Anti-Inflammatory Agents; Antifungal Agents; Child; Child, Preschool; Diflucortolone; Environmental Exposure; Family Health; Female; Fluconazole; Humans; Male; Miconazole; Naphthalenes; Pets; Terbinafine; Tinea; Treatment Outcome; Trichophyton

Many tinea inguinalis infections are characterized by pronounced inflammatory lesions and pruritus. Therefore, a therapy with a topical corticosteroid in addition to a topical antimycotic agent might be beneficial. In this multicenter, retrospective study, we compared the mycological and clinical efficacy and tolerability of isoconazole nitrate alone vs isoconazole nitrate and diflucortolone valerate in 58 adult patients with tinea inguinalis.. Treatment duration was three weeks. The efficacy of the treatment was based on the assessment of several signs and symptoms, which were collected on a 4-point scale. All patients were examined clinically before the beginning of the treatment, one week later, two weeks later, and at the end of the treatment. Mycological examinations were performed before the beginning of the treatment and at the end of the study.. Treatment results with the combination of isoconazole nitrate and diflucortolone valerate were superior regarding erythema and pruritus. Both erythema and pruritus resolved in a larger percentage of patients and more quickly. Both regimens were well tolerated. Mycological cure rates were similar in both groups of patients.. Combination therapy with isoconazole nitrate and diflucortolone valerate is an effective and well-tolerated regimen in adult patients with tinea inguinalis.

Topics: Administration, Cutaneous; Adolescent; Adult; Antifungal Agents; Diflucortolone; Drug Therapy, Combination; Erythema; Humans; Male; Miconazole; Middle Aged; Pruritus; Retrospective Studies; Time Factors; Tinea; Treatment Outcome; Young Adult

Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Antifungal Agents; Dermatomycoses; Diflucortolone; Drug Combinations; Drug Therapy, Combination; Global Health; Humans; Internationality; Miconazole; Tinea; Treatment Outcome

Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents; Antifungal Agents; Diflucortolone; Drug Combinations; Drug Therapy, Combination; Groin; Humans; Male; Miconazole; Skin; Tinea; Treatment Outcome

Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Antifungal Agents; Diflucortolone; Drug Combinations; Drug Therapy, Combination; Groin; Humans; Male; Miconazole; Middle Aged; Ointments; Skin; Tinea; Treatment Outcome; Trichophyton

Topics: Aged; Anti-Inflammatory Agents; Antifungal Agents; Diflucortolone; Drug Combinations; Drug Therapy, Combination; Groin; Humans; Male; Miconazole; Ointments; Skin; Tinea; Treatment Outcome

Topics: Administration, Cutaneous; Aged; Anti-Inflammatory Agents; Antifungal Agents; Diflucortolone; Drug Combinations; Drug Therapy, Combination; Humans; Leg; Male; Miconazole; Ointments; Skin; Thorax; Tinea; Treatment Outcome; Trichophyton

Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Antifungal Agents; Back; Child; Diflucortolone; Drug Combinations; Drug Therapy, Combination; Female; Humans; Miconazole; Ointments; Skin; Tinea; Treatment Outcome; Trichophyton

Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents; Antifungal Agents; Diflucortolone; Drug Combinations; Drug Therapy, Combination; Foot Dermatoses; Humans; Leg; Male; Miconazole; Ointments; Onychomycosis; Skin; Tinea; Treatment Outcome; Trichophyton

Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents; Antifungal Agents; Breast; Candida; Candidiasis, Cutaneous; Diflucortolone; Drug Combinations; Drug Therapy, Combination; Female; Humans; Imidazoles; Intertrigo; Miconazole; Ointments; Skin; Treatment Outcome

Topics: Aged; Anti-Inflammatory Agents; Antifungal Agents; Axilla; Candida; Candidiasis, Cutaneous; Diflucortolone; Drug Combinations; Drug Therapy, Combination; Humans; Intertrigo; Male; Miconazole; Ointments; Skin; Treatment Outcome

Topics: Adult; Anti-Inflammatory Agents; Antifungal Agents; Balanitis; Candida albicans; Candidiasis, Cutaneous; Diflucortolone; Drug Combinations; Drug Therapy, Combination; Eczema; Genitalia, Male; Humans; Intertrigo; Male; Miconazole; Ointments; Treatment Outcome

Topics: Adult; Anti-Inflammatory Agents; Antifungal Agents; Diflucortolone; Drug Combinations; Drug Therapy, Combination; Humans; Male; Miconazole; Ointments; Skin; Tinea Pedis; Toes; Treatment Outcome

Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents; Antifungal Agents; Diflucortolone; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Foot; Humans; Male; Miconazole; Ointments; Skin; Tinea Pedis; Treatment Outcome

Topics: Adolescent; Adult; Aged; Antifungal Agents; Dermatomycoses; Diflucortolone; Drug Combinations; Drug Evaluation; Female; Humans; Male; Miconazole; Middle Aged; Ointments; Time Factors

More than 10 years ago, diflucortolone valerate (Nerisone, Nerisona) was introduced in Germany and soon after in Asian countries in a concentration of 0.1% in cream, ointment and fatty ointment bases. 897 patients were included in the first Southeast Asian multicentre trial with these 3 formulations, and good efficacy and tolerability combined with a rapid onset of effect were shown. These results were confirmed later in Indonesia in an extended follow-up trial which included 1295 patients. A combination of 0.1% diflucortolone valerate with 1.0% chlorquinaldol was introduced after a multicentre Southeast Asian trial involving 8668 patients with inflammatory or allergic skin conditions for which a supplementary anti-infective treatment, for prophylaxis or therapy, was considered to be indicated. Excellent results were obtained in terms of efficacy, tolerability and cosmetic properties. A randomised double-blind trial comparing this preparation with a so-called 'shotgun' combination containing 0.05% betamethasone 17-valerate, 0.1% gentamicin, 1.0% tolnaftate and 1.0% clioquinol in 288 patients in the Philippines resulted in a better efficacy for the diflucortolone preparation in the 80 patients with bacterially or mycotically infected skin diseases. A 0.3% concentration of diflucortolone valerate was developed and introduced as a high potency topical corticosteroid. A trial in the Philippines which involved 143 patients with mostly severe chronic recurrent and resistant corticosteroid-responsive skin disease confirmed a pronounced clinical efficacy with a low incidence of side effects. For the treatment of inflammatory or eczematised dermatomycosis. 0.1% diflucortolone was combined with 1.0% isoconazole nitrate (Travocort). In a randomised double-blind study of 294 patients in Thailand, this preparation was compared with a plain 1.0% clotrimazole formulation. The results were significantly better for the diflucortolone plus isoconazole nitrate combination in terms of remission of symptoms, and after 1 week the mycological cure rates were also better, as shown in potassium hydroxide and culture investigations. It is concluded, therefore, that diflucortolone valerate in the available galenic bases and in effective combinations with other agents has been proven in extensive clinical trials to be a valuable therapeutic tool in dermatological practice.

Topics: Asia; Chlorquinaldol; Dermatomycoses; Diflucortolone; Fluocortolone; Humans; Miconazole; Ointments; Skin Diseases